vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and GCI Liberty, Inc. (GLIBA). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $257.0M, roughly 1.9× GCI Liberty, Inc.). CLOVER HEALTH INVESTMENTS, CORP. runs the higher net margin — -10.1% vs -150.6%, a 140.5% gap on every dollar of revenue. GCI Liberty, Inc. produced more free cash flow last quarter ($21.0M vs $-69.0M).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

GCI Communication Corp (GCI) is a telecommunications corporation operating in Alaska. Through its own facilities and agreements with other providers, GCI provides Internet access, landline, and cellular telephone service. It is a subsidiary of GCI Liberty, Inc.

CLOV vs GLIBA — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.9× larger
CLOV
$487.7M
$257.0M
GLIBA
Higher net margin
CLOV
CLOV
140.5% more per $
CLOV
-10.1%
-150.6%
GLIBA
More free cash flow
GLIBA
GLIBA
$90.0M more FCF
GLIBA
$21.0M
$-69.0M
CLOV

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CLOV
CLOV
GLIBA
GLIBA
Revenue
$487.7M
$257.0M
Net Profit
$-49.3M
$-387.0M
Gross Margin
Operating Margin
-10.1%
-189.9%
Net Margin
-10.1%
-150.6%
Revenue YoY
44.7%
Net Profit YoY
-123.2%
EPS (diluted)
$-13.34

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
GLIBA
GLIBA
Q4 25
$487.7M
Q3 25
$496.6M
$257.0M
Q2 25
$477.6M
$261.0M
Q1 25
$462.3M
Q4 24
$337.0M
Q3 24
$331.0M
Q2 24
$356.3M
Q1 24
$346.9M
Net Profit
CLOV
CLOV
GLIBA
GLIBA
Q4 25
$-49.3M
Q3 25
$-24.4M
$-387.0M
Q2 25
$-10.6M
$27.0M
Q1 25
$-1.3M
Q4 24
$-22.1M
Q3 24
$-9.2M
Q2 24
$7.4M
Q1 24
$-19.2M
Gross Margin
CLOV
CLOV
GLIBA
GLIBA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
24.5%
Q2 24
30.3%
Q1 24
23.6%
Operating Margin
CLOV
CLOV
GLIBA
GLIBA
Q4 25
-10.1%
Q3 25
-4.9%
-189.9%
Q2 25
-2.2%
19.5%
Q1 25
-0.3%
Q4 24
-6.4%
Q3 24
-2.7%
Q2 24
2.0%
Q1 24
-6.5%
Net Margin
CLOV
CLOV
GLIBA
GLIBA
Q4 25
-10.1%
Q3 25
-4.9%
-150.6%
Q2 25
-2.2%
10.3%
Q1 25
-0.3%
Q4 24
-6.6%
Q3 24
-2.8%
Q2 24
2.1%
Q1 24
-5.5%
EPS (diluted)
CLOV
CLOV
GLIBA
GLIBA
Q4 25
Q3 25
$-13.34
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
GLIBA
GLIBA
Cash + ST InvestmentsLiquidity on hand
$78.3M
$124.0M
Total DebtLower is stronger
$985.0M
Stockholders' EquityBook value
$308.7M
$1.4B
Total Assets
$541.0M
$3.0B
Debt / EquityLower = less leverage
0.72×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
GLIBA
GLIBA
Q4 25
$78.3M
Q3 25
$124.0M
Q2 25
$104.0M
Q1 25
Q4 24
$194.5M
Q3 24
$288.0M
Q2 24
$254.8M
Q1 24
$208.3M
Total Debt
CLOV
CLOV
GLIBA
GLIBA
Q4 25
Q3 25
$985.0M
Q2 25
$987.0M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CLOV
CLOV
GLIBA
GLIBA
Q4 25
$308.7M
Q3 25
$340.9M
$1.4B
Q2 25
$344.2M
Q1 25
$336.1M
Q4 24
$341.1M
Q3 24
$342.2M
Q2 24
$324.9M
Q1 24
$292.5M
Total Assets
CLOV
CLOV
GLIBA
GLIBA
Q4 25
$541.0M
Q3 25
$559.7M
$3.0B
Q2 25
$575.0M
$3.4B
Q1 25
$583.7M
Q4 24
$580.7M
Q3 24
$653.0M
Q2 24
$674.2M
Q1 24
$671.8M
Debt / Equity
CLOV
CLOV
GLIBA
GLIBA
Q4 25
Q3 25
0.72×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
GLIBA
GLIBA
Operating Cash FlowLast quarter
$-66.9M
$76.0M
Free Cash FlowOCF − Capex
$-69.0M
$21.0M
FCF MarginFCF / Revenue
-14.1%
8.2%
Capex IntensityCapex / Revenue
0.4%
21.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
GLIBA
GLIBA
Q4 25
$-66.9M
Q3 25
$12.1M
$76.0M
Q2 25
$5.4M
$226.0M
Q1 25
$-16.3M
Q4 24
$34.8M
Q3 24
$50.0M
Q2 24
$44.8M
Q1 24
$25.9M
Free Cash Flow
CLOV
CLOV
GLIBA
GLIBA
Q4 25
$-69.0M
Q3 25
$11.4M
$21.0M
Q2 25
$4.8M
$107.0M
Q1 25
$-16.5M
Q4 24
$33.3M
Q3 24
$49.6M
Q2 24
$44.4M
Q1 24
$25.5M
FCF Margin
CLOV
CLOV
GLIBA
GLIBA
Q4 25
-14.1%
Q3 25
2.3%
8.2%
Q2 25
1.0%
41.0%
Q1 25
-3.6%
Q4 24
9.9%
Q3 24
15.0%
Q2 24
12.5%
Q1 24
7.3%
Capex Intensity
CLOV
CLOV
GLIBA
GLIBA
Q4 25
0.4%
Q3 25
0.1%
21.4%
Q2 25
0.1%
45.6%
Q1 25
0.0%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Q1 24
0.1%
Cash Conversion
CLOV
CLOV
GLIBA
GLIBA
Q4 25
Q3 25
Q2 25
8.37×
Q1 25
Q4 24
Q3 24
Q2 24
6.04×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons